Switching from Oral Risperidone 3mg to Paliperidone LAI
For a patient stable on oral risperidone 3mg daily, initiate paliperidone palmitate (Invega Sustenna) with 234mg deltoid injection on Day 1, followed by 156mg deltoid injection on Day 8, then continue with 117mg monthly maintenance doses—no oral supplementation is required. 1
Dosing Strategy
The FDA-approved conversion follows a straightforward algorithm:
- Day 1: Administer 234mg paliperidone palmitate into the deltoid muscle
- Day 8 (±2 days acceptable): Administer 156mg into the deltoid muscle
- Monthly maintenance (starting 4 weeks after Day 8 dose): Administer 117mg into either deltoid or gluteal muscle
Dose Selection Rationale
The 117mg monthly maintenance dose corresponds to your patient's 3mg daily risperidone based on pharmacokinetic modeling showing a 25-fold conversion factor. 2 Specifically, risperidone 3mg daily produces similar steady-state exposure to paliperidone palmitate 75mg equivalent (which equals 117mg of the palmitate salt). 1, 2
Critical Implementation Details
Oral Medication Discontinuation
Discontinue oral risperidone the day before or on the same day as the first paliperidone injection. 1 The FDA label explicitly states that previous oral antipsychotics can be gradually discontinued at the time of initiation, and no oral supplementation is required with the loading dose regimen. 1
Important Caveat About Bridging
While the FDA label does not recommend bridging, one retrospective study found that patients on risperidone ≥4mg daily who received oral bridging for ≥7 days after the first injection had fewer hospitalization days. 3 However, your patient is on 3mg daily, which falls below this threshold, making bridging unnecessary.
Injection Site and Needle Selection
For the Day 1 and Day 8 loading doses, use the deltoid muscle exclusively:
- If patient weighs <90kg: Use 1-inch 23-gauge needle (blue hub)
- If patient weighs ≥90kg: Use 1.5-inch 22-gauge needle (gray hub)
For monthly maintenance doses, either deltoid or gluteal sites are acceptable. 1
Tolerability Considerations
Since paliperidone is the major active metabolite of risperidone, tolerability should already be established on the current oral regimen. 1 The FDA label notes that for patients who have never taken oral paliperidone or risperidone, tolerability should be established first—but this does not apply to your patient who is already stable on risperidone.
Pharmacogenetic Consideration
Be aware that rare cases of psychotic relapse have occurred when switching from risperidone to paliperidone, potentially related to CYP2D6 polymorphisms affecting the risperidone-to-paliperidone conversion ratio. 4 If your patient experiences unexpected symptom worsening despite appropriate dosing, consider this possibility and potentially revert to risperidone.
Dose Adjustments
The maintenance dose can be adjusted within the range of 39mg to 234mg monthly based on tolerability and efficacy. 1 However, starting at 117mg is appropriate given the established stability on risperidone 3mg daily.
Special Populations
- Mild renal impairment (CrCl 50-80 mL/min): Reduce loading doses to 156mg Day 1 and 117mg Day 8, with 78mg monthly maintenance (maximum 156mg monthly) 1
- Moderate/severe renal impairment: Paliperidone LAI is not recommended 1
- Hepatic impairment: No dose adjustment needed for mild-to-moderate impairment 1
Timing Flexibility
Monthly maintenance injections can be administered ±7 days from the scheduled date without clinically significant impact on plasma concentrations. 5, 6 This provides practical flexibility for appointment scheduling while maintaining therapeutic coverage.